Ind-Swift Laboratories Limited (INDSWFTLAB) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Ind-Swift Laboratories Limited ₹68.82, price ₹395, upside -82.6%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ind-Swift Laboratories Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ₹53.40 – ₹413.10 · fair‑value band ₹58.07 – ₹86.02 · the ₹395.15 price screens above the ₹68.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Ind-Swift Laboratories in your weekly email
Every Wednesday you see whether Ind-Swift Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally.
Show more
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.
Stock analysis
Ind-Swift Laboratories Limited (INDSWFTLAB) currently trades at ₹395.15, while our model-based Fair Value estimate is ₹68.82, 82.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹106.63 per share, and 2 of the 13 models we run sit above the ₹395.15 price.
Bear case: the Earnings-Based group reads lowest at ₹55.61, and 11 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹58.07 (bear) to ₹86.02 (bull), the price of ₹395.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Ind-Swift Laboratories Limited reported revenue of ₹6.4B in FY2026 versus ₹10.4B in FY2022, a compound −11.4%/yr. Reported net income was ₹414M in FY2026.
Key figures
Market cap ₹33.8B (≈ $351M) · P/E ratio 59.1 · P/S ratio 3.81 · EPS (TTM) ₹6.69 · Net margin 6.5% · Return on equity 3.2% · Return on assets (EBIT) 5.3% · Operating margin 13.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 4% below its 52-week high and 348% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −83%, INDSWFTLAB screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹55.61 to ₹4,998). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹58.07Fair Value ₹68.82Bull ₹86.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹3.39 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+14.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
Start year 2021 (pandemic). Over 10 years: −0.2% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 3 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−50.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−50.4%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 2%
⚠ Revenue per share shrinking 5.1%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Ind-Swift Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 620 stocks
Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside−82.6% · Bottom 25%
Profitability
Return on equity (TTM)3.2% · Below median
Return on assets0.6% · Below median
Net margin (TTM)8.5% · Above median
Operating margin (TTM)13.5% · Above median
Growth and dividend
Revenue growth25.4% · Top 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)59.1× · Priciest 25%
P/B2.44× · Pricier than median
P/S (TTM)5.01× · Priciest 25%
EV/EBITDA42.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)100· sector 20
PAST (return on equity)13· sector 26
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Ind-Swift Laboratories Limited (INDSWFTLAB) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹68.82 versus a price of ₹395.15, about −83% upside (overvalued).
What is the fair value of INDSWFTLAB?
Our model-based fair value for Ind-Swift Laboratories Limited is ₹68.82 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹395.15.
What is the quality score of INDSWFTLAB?
Ind-Swift Laboratories Limited has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ind-Swift Laboratories Limited (INDSWFTLAB)?
Our model-based price target is the fair value of ₹68.82 (as of Oct 1, 2026) from 13 valuation models. Cautious scenario ₹58.07, optimistic scenario ₹86.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Ind-Swift Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹68.82, about −83% upside versus a price of ₹395.15 (overvalued). Cautious scenario ₹58.07, optimistic scenario ₹86.02. The calculation is refreshed regularly with new filings.
What is the revenue of Ind-Swift Laboratories Limited (INDSWFTLAB)?
Ind-Swift Laboratories Limited reported trailing-twelve-month revenue of about ₹6.7B (latest available figure, as of Oct 1, 2026).
What is the intrinsic value of Ind-Swift Laboratories Limited (INDSWFTLAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ind-Swift Laboratories Limited it is ₹68.82 per share (as of Oct 1, 2026), against a price of ₹395.15. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Ind-Swift Laboratories Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, INDSWFTLAB trades above its calculated fair value: price ₹395.15, fair value ₹68.82, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INDSWFTLAB?
No. The price is what the market pays today (₹395.15); the fair value is what the company's own numbers justify (₹68.82). For Ind-Swift Laboratories Limited the two are ₹326.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ind-Swift Laboratories Limited worth?
The market values Ind-Swift Laboratories Limited at about ₹33.8B (market capitalisation, as of Oct 1, 2026). Per share that is ₹395.15; our models calculate a fair value of ₹68.82 per share.
What do the bullish and bearish scenarios say about INDSWFTLAB?
Our models span a range for Ind-Swift Laboratories Limited: cautious scenario ₹58.07, base ₹68.82, optimistic ₹86.02 per share (as of Oct 1, 2026, price ₹395.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of INDSWFTLAB?
Ind-Swift Laboratories Limited trades at a price-to-earnings ratio of 59.1 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹68.82 is built from several models across several years. Other multiples: P/B 2.4, P/S 5.0, EV/EBITDA 42.0.
How solid is the balance sheet of Ind-Swift Laboratories Limited (INDSWFTLAB)?
Balance-sheet figures for Ind-Swift Laboratories Limited (as of Oct 1, 2026): return on equity 3.2%, debt of 0.01 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is INDSWFTLAB from its 52-week high?
Ind-Swift Laboratories Limited trades at ₹395.15, about 4% below its 52-week high of ₹413.10 and 348% above the low of ₹88.15 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹68.82 is for.
Which stocks are comparable to Ind-Swift Laboratories Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ind-Swift Laboratories Limited stock attractive at the current price?
The data as of Oct 1, 2026: price ₹395.15, calculated fair value ₹68.82 (−83%), Quality Score 28/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INDSWFTLAB calculated?
We run Ind-Swift Laboratories Limited through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹68.82, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Ind-Swift Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ind-Swift Laboratories Limited (INDSWFTLAB)?
The closing price on Oct 1, 2026 was ₹395.15. Our model-based fair value is ₹68.82, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ind-Swift Laboratories Limited right now?
The price sits above even our optimistic bull case (₹86.02). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Ind-Swift Laboratories Limited
How large is the market capitalisation of Ind-Swift Laboratories Limited (INDSWFTLAB)?
The market capitalisation of Ind-Swift Laboratories Limited is ₹33.8B (≈ $351M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ind-Swift Laboratories Limited (INDSWFTLAB)?
The price-to-sales ratio of Ind-Swift Laboratories Limited is 3.81 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ind-Swift Laboratories Limited (INDSWFTLAB)?
Earnings per share at Ind-Swift Laboratories Limited are ₹6.69 (price ÷ EPS = P/E 59.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ind-Swift Laboratories Limited (INDSWFTLAB)?
The net margin of Ind-Swift Laboratories Limited is 6.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ind-Swift Laboratories Limited (INDSWFTLAB)?
The return on equity (ROE) of Ind-Swift Laboratories Limited is 3.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ind-Swift Laboratories Limited (INDSWFTLAB)?
On an EBIT basis the return on assets of Ind-Swift Laboratories Limited is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ind-Swift Laboratories Limited (INDSWFTLAB)?
The operating margin of Ind-Swift Laboratories Limited is 13.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ind-Swift Laboratories Limited (INDSWFTLAB)?
Revenue at Ind-Swift Laboratories Limited is growing +25.4% versus a year earlier (3y avg −19.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ind-Swift Laboratories Limited (INDSWFTLAB)?
Earnings per share at Ind-Swift Laboratories Limited are growing +143% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Ind-Swift Laboratories Limited (INDSWFTLAB) generate?
The free cash flow of Ind-Swift Laboratories Limited is −₹1.1B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Ind-Swift Laboratories Limited (INDSWFTLAB) hold?
Ind-Swift Laboratories Limited holds more cash than debt, ₹4.1B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Ind-Swift Laboratories Limited in the live analysis
One click puts Ind-Swift Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
